New biomarkers found for cystic fibrosis
Canadian researchers have identified several unknown chemicals that were consistently associated with babies who had cystic fibrosis (CF), including two different drug and environmental compounds the infants secreted in sweat at much lower concentration levels…
Canadian researchers McMaster University have identified several unknown chemicals beyond chloride that were consistently associated with babies who had cystic fibrosis (CF), including two different drug and environmental compounds the infants secreted in sweat at much lower concentration levels.
Scientists collected and analysed sweat samples from infants in CF clinics at the McMaster Children’s Hospital and the Hospital for Sick Children in Toronto. The findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers at McMaster University.
“There are chemical signatures in sweat that tell us an infant has CF,” said Philip Britz-McKibbin, lead author of the study and a professor in the Department of Chemistry and Chemical Biology at McMaster University. “We set out to discover whether there were chemical indicators detected in sweat that could complement the gold standard for CF diagnosis: the sweat chloride test.”
The test is commonly used in universal new-born disease-screening programs and measures the concentrations of salt. Elevated sweat chloride confirms that an infant actually has CF. But there are some obstacles that complicate clinical decision-making, explains Prof Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.
“Sweat contains lots of information related to human health that researchers have not fully analysed and we found some unexpected chemicals associated with CF,” said Prof Britz-McKibbin.
The biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.”The easier it is to detect CF, the earlier it can be diagnosed, and the better people’s chances are at living a longer, healthier life”, says Joanna Valsamis, Chief Healthcare, Research and Advocacy Officer at Cystic Fibrosis Canada.